Supplementary data for

N6-methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming

Chen et al
Figure S1 ERRγ is upregulated in chemoresistant cancer cells.

(A&B) Cell proliferation measured in HepG2/ADR (A) or MCF-7/ADR (B) and their corresponding parental cells treated with increasing concentrations of Dox for 48 h;

(C) Protein expression of ERRα in HepG2/ADR, MCF-7/ADR cells, and their corresponding parental cells measured by Western blot analysis (left) and quantitatively analyzed (right);

(D) The mRNA expression of ERRγ was measured in MCF-7/Tax, MDA-MB-231/Tax, A549/Tax and their corresponding parental cells by qRT-PCR;

(E) The protein expression of ERRγ in MCF-7/Tax, MDA-MB-231/Tax, and their corresponding parental cells was checked by Western blot analysis;

(F) The subcellular expression of ERRγ in MCF-7/Dox and MCF-7 cells was checked by confocal imaging;

(G) Cells were treated with Dox (2 μM) for the indicated time, then protein expression of ERRα was checked by Western blot analysis.
Data were presented as means ± SD from three independent experiments. **p < 0.01 compared with control.

**Related to Figure 1**

**Figure S2 ERRγ regulates chemoresistance of cancer cells.**

(A) Cells were transfected with si-NC or si-ERRγ-1/2/3 for 24 h. The expression of ERRγ was checked by Western blot analysis (left) and quantitatively analyzed (right). The si-ERRγ-1/2 were used for next studies due to the relative high efficiency;

(B) Cells were transfected with vector control or pcDNA/ERRγ for 24 h and the expression of ERRγ was checked by Western blot analysis;

(C&D) Cell proliferation rate of HepG2 cells transfected with vector control or pcDNA/ERRγ for 24 h, followed by treatment with increasing concentrations of Dox (C) or Tax (D).
(E&F) Cell proliferation rate of MCF-7 cells transfected with vector control or pcDNA/ERRγ for 24 h, followed by treatment with increasing concentrations of Dox (E) or Tax (F) for 48 h;

(G) Protein levels of ERRγ in cells transfected with sh-Con or sh-ERRγ was checked by Western blot analysis (left) and quantitatively analyzed (right).

Data were presented as means ± SD from three independent experiments. **p< 0.01.

Related to Figure 2.

Figure S3 P-gp is involved in ERRγ-regulated chemoresistance of cancer cells.

(A) MCF-7/Tax or MDA-MB-231/Tax cells were transfected with scrambled siRNA or si-ERRγ-1/2 for 24 h and the expression of ERRγ and ABCB1 was measured by qRT-PCR;

(B) HepG2/ADR or MCF-7/ADR cells were co-transfected with si-NC, si-ERRγ-1, vector control or pcDNA/ABCB1 construct alone or together for 24 h and the expression of ERRγ and P-gp was measured by Western blot analysis.

Data were presented as means ± SD from three independent experiments. **p< 0.01. NS, no significant.

Related to Figure 3.
Figure S4 ERRγ interacts with p65 to regulate ABCB1 transcription.

(A) Interaction between ERRγ and p65 in HepG2/ADR cells was checked by immunoprecipitation using a p65 antibody;

(B&C) HepG2/ADR or MCF-7/ADR cells were treated with or without BAY 11-7082 (10 μM) for 24 h and the mRNA (B) and protein (C) of P-gp were checked by qRT-PCR and Western blot analysis, respectively.

Data were presented as means ± SD from three independent experiments. **p < 0.01. NS, no significant.

Related to Figure 4
Figure S5 ERRγ dictates the metabolic reprogramming in chemoresistant cancer cells.

(A) Extracellular acidification rate (ECAR) of HepG2/ADR or HepG2 cells was assessed following the addition of 10 mM glucose, 1 μM oligomycin, and 50 mM 2-Deoxy glucose (2-DG) by use of a Seahorse XF24 analyzer;

(B) The relative mitochondrial mass of HepG2/ADR or HepG2 cells;

(C) ECAR of HepG2/ADR transfected with sh-Con or sh-ERRγ was measured by a Seahorse XF24 analyzer;

(D~E) The OCR (D) or ECAR (E) of HepG2 cells transfected with vector control of pcDNA/ERRγ for 24 h was measured by a Seahorse XF24 analyzer.

(F) HepG2 cells were transfected with pcDNA or pcDNA/ERRγ for 24 h and the expression of genes related to OxPhos was checked;

(G) The expression of genes related to OxPhos was checked in HepG2/ADR cells transfected with sh-Con or sh-ERRγ.

Data were presented as means ± SD from three independent experiments. **p< 0.01. NS, no
Figure S6 ERRγ regulates the FAO via Cpt1b in chemoresistant cancer cells.

(A) HepG2 cells were transfected with vector or pcDNA/ERRγ for 24 h and the mRNA expression of CPT1B was checked by qRT-PCR;

(B) HepG2/ADR cells were transfected with si-NC or si-ERRγ-1/2 for 24 h and the protein expression of Cpt1b was checked by Western blot analysis and quantitatively analyzed;

(C) HepG2/ADR cells transfected with sh-Con or sh-ERRγ were further transfected with vector or CPT1B construct for 24 h and the protein expression was checked by Western blot analysis;

(D&E) HepG2/ADR or MCF-7/ADR cells were treated with or without BAY 11-7082 for 24 h and the mRNA (D) and protein (E) expression of Cpt1b was checked.

Data were presented as means ± SD from three independent experiments. **p< 0.01. NS, no significant.

Related to Figure 6.
Figure S7 The m^6A-facilitated splicing is responsible for the upregulation of ERRγ.

(A) Cells were treated with or without 5 µM 5-aza-dC for 4 days, the expression of ERRγ was tested;

(B) Cells were treated with or without SAHA (2 µM), or NaB (2 mM) for 24 h, the expression of ERRγ was tested;

(C) HepG2 cells were transfected with vector control or Mettl3 constructs for 24 h, the expression of ERRγ was tested;

(D) Cells were treated with CHX for the indicated times, and protein expression of ERRγ was analyzed by western blot analysis (left) and quantitatively analyzed (right);

(E) Cells were transfected with vector control or Mettl3 constructs for 24 h, the mature mRNA expression of ERRγ was tested;
(F) HepG2/ADR cells were transfected with sh-con or sh-Mettl3 constructs for 24 h, the subcellular localization of mature mRNA of ERRγ was tested;

(G) HepG2/ADR cells transfected with sh-Con or sh-Mettl3 were pre-treated with Act-D for 90 min, then the mature mRNA of ERRγ was checked by qRT-PCR.

Data were presented as means ± SD from three independent experiments. **p< 0.01. NS, no significant.

Related to Figure S7.

Figure S8 The m⁶A/ ERRγ axis and in vivo cancer progression.

(A) Expression of ESRRG in normal and breast cancer tissues from Oncomine database (Finak breast)

(B) Correlation between ESRRG and ABCB1 in breast cancer patients (n=880) from TCGA database;

Relative to Figure 8.
### Supplementary Table 1 The official full name and function of FAO related genes [1]

<table>
<thead>
<tr>
<th>Catalog</th>
<th>Function</th>
<th>Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyl-CoA synthetase (long-chain)</td>
<td>Convert free long chain fatty acids into fatty acyl-CoA esters</td>
<td>ACSL4, ACSL5</td>
</tr>
<tr>
<td>Carnitine palmitoyltransferase</td>
<td>Promote carnitine dependent transport across the mitochondrial membrane</td>
<td>CPT1A, CPT1B, CPT1C, CPT2</td>
</tr>
<tr>
<td>Carnitine O-acetyltransferase</td>
<td>Regulate the acyl-CoA/CoA ratio</td>
<td>CRAT</td>
</tr>
<tr>
<td>Acyl-CoA dehydrogenase (C-2 to C-3)</td>
<td>Catalyze the initial step of FAO</td>
<td>ACADS, ACAD9</td>
</tr>
<tr>
<td>Acyl-CoA dehydrogenase (C-4 to C-12)</td>
<td>Catalyze the initial step of FAO</td>
<td>ACADM, ACAD10</td>
</tr>
<tr>
<td>Acyl-CoA dehydrogenase (long chain)</td>
<td>Catalyze the initial step of FAO</td>
<td>ACADL, ACAD11</td>
</tr>
<tr>
<td>Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase</td>
<td>Catalyze the last three steps of FAO</td>
<td>HADHA, HADHB</td>
</tr>
<tr>
<td>Acetyl-CoA acyltransferase 2</td>
<td>Catalyze the last step of FAO</td>
<td>ACAA2</td>
</tr>
<tr>
<td>Enoyl-CoA delta isomerase</td>
<td>Regulate FAO for unsaturated fatty acids</td>
<td>ECI1, ECI2</td>
</tr>
</tbody>
</table>

### Table S2 Primers for PCR assay

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>qRT-PCR</strong></td>
<td></td>
</tr>
</tbody>
</table>
| ESR1   | forward: 5’- GCTTACTGACCAACCTGACGA -3’  
          | reverse: 5’- GGATCTCTAGCCAGGACATTT -3’                     |
| ESR2   | forward: 5’- ATGGAGTCTGCTGTGAGAAGG -3’  
          | reverse: 5’- TAACACTTCCGAAGTCCGCAGG -3’                     |
| ESRRA  | forward: 5’- CCACTATGTTGTGGATCTCGCTGAGG -3’  
          | reverse: 5’- GGATCTCTAGCCAGGACATTT -3’                     |
| ESRRB  | forward: 5’- GACATTGCTCTGCTGCTACACT -3’  
          | reverse: 5’- CTCCGTTTGGTGATCGCTCGACT -3’                     |
| ESRRG  | forward: 5’- CGCAGGATAGATGCGAGAACA -3’  
          | reverse: 5’- TACAGCCACAAACAAATGAGAC -3’                     |
| GPER1  | forward: 5’- TTCCGGAGAAGATGACCATCC -3’  
          | reverse: 5’- TAGTACCGCTCTGCTGAGTGA -3’                     |
| ABCA1  | forward: 5’- CAGGCTACTACCTGACCTTTG -3’  
          | reverse: 5’- GTGCTCTGAGAATAACCTGCTTC -3’                     |
| ABCB1  | forward: 5’- GCTGTCAAGGAAAGCCAATGCT -3’  
<pre><code>      | reverse: 5’- GGATCTCTAGCCAGGACATTT -3’                     |
</code></pre>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCC1</td>
<td>5' - TGCAATGGCGATCCTCTGCTTC -3'</td>
<td>5' - TGCAATGGCGATCCTCTGCTTC -3'</td>
</tr>
<tr>
<td>ABCC2</td>
<td>5' - GCCAACCTTGTGGTGCTGATAGG -3'</td>
<td>5' - ATCCAGGACTGCTGTGGGACAT -3'</td>
</tr>
<tr>
<td>ABCC3</td>
<td>5' - GAGGAGAAAGCAGCCATTGGCA -3'</td>
<td>5' - GTTCTCAGCAGCTCTTCGGCTT -3'</td>
</tr>
<tr>
<td>ABCG2</td>
<td>5' - CACAGGGTATCAGCCGAACCAA -3'</td>
<td>5' - CCAATACCGCTGCCTTCTCTGT -3'</td>
</tr>
<tr>
<td>CS</td>
<td>5' - CAGGATCATGCTGGCTGCAAAG -3'</td>
<td>5' - CCAATACCGCTGCCTTCTCTGT -3'</td>
</tr>
<tr>
<td>NDUFA4</td>
<td>5' - CACTGTATCTCTTGCGTCTGGC -3'</td>
<td>5' - GCTTGCTGTAATCCACATTCACTG -3'</td>
</tr>
<tr>
<td>SDHB</td>
<td>5' - TCAGGCTGTGGGTCTCAATCCATTCAC -3'</td>
<td>5' - TCAGGCTGTGGGTCTCAATCCATTCAC -3'</td>
</tr>
<tr>
<td>COX5B</td>
<td>5' - GCAATGGTACATGCTGTGGCAAAAG -3'</td>
<td>5' - GCCAGCTACTATTCTTCTTGGG -3'</td>
</tr>
<tr>
<td>ATP5B</td>
<td>5' - TCATGCTGAGGCTGAGTACC -3'</td>
<td>5' - ACAGTCTTGGCAAACCTCAGAC -3'</td>
</tr>
<tr>
<td>ACAA2</td>
<td>5' - TCACGAATTTAGGCCTGGGAGGTG -3'</td>
<td>5' - GCAGCCATACATCCATCACTAC -3'</td>
</tr>
<tr>
<td>ACAD10</td>
<td>5' - CAGCCACAGACGAGCCATATACAC -3'</td>
<td>5' - GCAGCCATACATCCATCACTAC -3'</td>
</tr>
<tr>
<td>ACAD11</td>
<td>5' - CAGCCACAGACGAGCCATATACAC -3'</td>
<td>5' - GCAGCCATACATCCATCACTAC -3'</td>
</tr>
<tr>
<td>ACAD9</td>
<td>5' - CACAGGGTATCAGCCGAACCAA -3'</td>
<td>5' - CCAATACCGCTGCCTTCTCTGT -3'</td>
</tr>
<tr>
<td>ACADL</td>
<td>5' - TGCTGTGTCGCTGTGGGAGG -3'</td>
<td>5' - CACAGGGTATCAGCCGAACCAA -3'</td>
</tr>
<tr>
<td>ACADM</td>
<td>5' - TGGCTGCTGAGGCTGAGTACC -3'</td>
<td>5' - CCAATACCGCTGCCTTCTCTGT -3'</td>
</tr>
<tr>
<td>ACADS</td>
<td>5' - TCAGGCTGTGGGTCTCAATCCATTCAC -3'</td>
<td>5' - CACAGGGTATCAGCCGAACCAA -3'</td>
</tr>
<tr>
<td>ACSL4</td>
<td>5' - TGGCTGCTGAGGCTGAGTACC -3'</td>
<td>5' - CCAATACCGCTGCCTTCTCTGT -3'</td>
</tr>
<tr>
<td>ACSL5</td>
<td>5' - TGCTGTGTCGCTGTGGGAGG -3'</td>
<td>5' - CACAGGGTATCAGCCGAACCAA -3'</td>
</tr>
<tr>
<td>CPT1A</td>
<td>5' - ATCCAGGATGTCACAGCTCAGTTT -3'</td>
<td>5' - CACAGGGTATCAGCCGAACCAA -3'</td>
</tr>
<tr>
<td>CPT1B</td>
<td>5' - GCAATGGTACATGCTGTGGCAAAAG -3'</td>
<td>5' - GCCAGCTACTATTCTTCTTGGG -3'</td>
</tr>
<tr>
<td>CPT1C</td>
<td>5' - CGGCGTTGATCTCAGCTCCTGAGTACC -3'</td>
<td>5' - CACAGGGTATCAGCCGAACCAA -3'</td>
</tr>
<tr>
<td>Gene</td>
<td>Forward Primer</td>
<td>Reverse Primer</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>CPT2</td>
<td>5' - GTGATGGTGTGGCACGTGCTG -3'</td>
<td>5' - TGGCTGGCTTGTGGAGTGA -3'</td>
</tr>
<tr>
<td>CRAT</td>
<td>5' - AGGTGGAGCTGCTGCGGAAG -3'</td>
<td>5' - ATGGCGATGCGGATAGGAGGTG -3'</td>
</tr>
<tr>
<td>ECI1</td>
<td>5' - TCCAACCTGGTGCTGGCTCCT -3'</td>
<td>5' - AGGATGCGGTAGTCACAGCTCAG -3'</td>
</tr>
<tr>
<td>ECI2</td>
<td>5' - CAGGCCACTGAAGGACCTTGTAAC -3'</td>
<td>5' - GGCTCCACCTGACTAGAGGATTCC -3'</td>
</tr>
<tr>
<td>HADHA</td>
<td>5' - CATGGTCAGGTCTGCGCAAG -3'</td>
<td>5' - GGCTCCACCTGACTAGAGGATTCC -3'</td>
</tr>
<tr>
<td>HADHB</td>
<td>5' - CTGACAAGACTCTCCTGCTCACACTG -3'</td>
<td>5' - CACCACCTGACCAGATCACATC -3'</td>
</tr>
<tr>
<td>GAPDH</td>
<td>5' - ACAACTTTGGTGATGCTGGAAGGAAG -3'</td>
<td>5' - GCCATCACGCCAAGTTTC -3'</td>
</tr>
</tbody>
</table>
**Materials and Methods**

1. **Cell lines and cell culture**

   Human MCF-7, HepG2, MDA-MB-231, and A549 cancer cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and maintained in our lab with recommended medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen). The HepG2/ADR cells were obtained by treatment with gradually increasing concentration of Adriamycin (ADR) [2]. The MCF-7/ADR was also obtained by treatment with gradually increasing concentration of ADR and kindly provided by Cancer Institute & Hospital Chinese Academy of Medical Sciences (Beijing, China) [3]. The taxol (Tax) resistant MCF-7, MDA-MB-231, and A549 cells were purchased from Shanghai Institute of Cell Resource Center of Life Science (Shanghai, China). DNA fingerprinting was performed using the commercially PowerPlex# 1.2 System kit to confirm the source of chemoresistant cancer cells. Cells were maintained as monolayers in 5% CO₂ at 37 °C. When the cells were 80% confluent, they were sub-cultured to fresh medium. Cells were routinely tested for mycoplasma contamination using MycoAlert Mycoplasma Detection Kit. The cultures were incubated for 24 h before the experimental treatments.

2. **qRT-PCR**

   RNA extraction with Trizol (Invitrogen) and real-time PCR were performed according to the protocols used in our previous study [4]. Quantitative Real-Time PCR (qRT-PCR) was implemented with an iCycler (Bio-Rad, Hercules, USA) using validated primers and SYBR Premix Ex Taq II (Takara, Japan). GAPDH were used as an endogenous control for normalization. Expression levels were calculated using the $2^{-\Delta\Delta Ct}$ method. Three independent experiments were performed. Primer pairs were summarized at Table S2 in the Supplementary Data.

3. **Western blot analysis**

   Western blot analysis was performed according to the protocol used in our previous study [5]. The antibodies used in the present study were: ERRα (Santa Cruz Biotechnology, sc-65715, 1:1000), ERRγ (Santa Cruz Biotechnology, sc-393969, 1:1000), H2A.X (CST, 7631S,
For measuring the subcellular localization of ERRγ, the nucleus and cytosol were separated by using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific, Inc., Pierce, Waltham, MA, USA). GAPDH and H2A.X were used as the loading control for cytosol and nucleus, respectively. GAPDH and α-tubulin were used as the loading control for normalization. The quantitative analysis of Western blot analysis was conducted according to the previous study [6]. Briefly, the intensity of the bands on the blots was measured using Image Lab (Bio-Rad). The intensity values of target proteins were divided by the intensity values of internal control (GAPDH or α-tubulin). The obtained intensity value from control cells was set to 100% with n=3 for each group unless otherwise specified. One of representative Western blot experiments is shown.

4. Immunofluorescence

Immunofluorescent staining was performed as described previously [7]. Briefly, cells growing on the coverslips were washed with PBS, fixed in 4% paraformaldehyde for 15 min and treated with 0.3% triton-x in PBS for 5 min. Cells were blocked with 3% BSA for 1 h at room temperature and incubated with the specific primary antibodies and accordingly dye-conjugated secondary antibody. Finally, cells were counterstained with DAPI (Vector Laboratories, Burlingame, CA). Fluorescent images were acquired using Leica SP8 confocal microscope.

5. Cell proliferation and colony formation

Cell proliferation was tested by CCK-8 kit (Dojindo, Gaithersburg, MD) according to our previous study [7]. Colony formation was detected by CytoSelect 96-well Cell Transformation Assay (Cell Biolabs, USA).

6. Plasmid, siRNA, shRNA and generation of stable cell lines

The small interfering RNA against ERRγ (si-ERRγ) and its negative control (si-NC) were
purchased from RiBo Biotech (Guangzhou RiBo Biotech). Plasmid expressing small hairpin RNA against ERRγ (sh-ERRγ) or Mettl3 (sh-Mettl3) scramble shRNA-encoding plasmid were obtained by GenePharm Co. Ltd. (Shanghai, China). The pcDNA/ERRγ and pcDNA/CPT1B was constructed in our lab by inserting the full length of ERRγ and CTP1B into the pcDNA3.1 vector. Twenty-four hours before transfection, the medium was replaced with fresh medium and transfected using Lipofectamine 2000 reagent (Invitrogen) with vector control, plasmid construct, siRNA negative control (si-NC), or siRNAs according to the manufacturer’s instructions. The working concentration of siRNA was 50 nM.

To generate ERRγ knockdown cells, cells were transfected with scramble control or sh-ERRγ lentivirus were selected with 1 μg/ml puromycin for two weeks. The stable cells were cultured in medium supplemented with 1 μg/ml puromycin. Cells were incubated with medium without puromycin for four days before experiments.

7. Rh123 accumulation assay

Rh123 accumulation assay was used to assess the P-gp function according to the previous study [8]. Briefly, cells were treated as indicated conditions and then incubated with Rh123 (10 μM) for 30 min/37°C and analyzed by flow cytometry (FACSCanto, BD Biosciences) at 510 nm excitation/595 nm emission. Data were collected from 10 000 cells per sample.

8. Immunoprecipitation

After lysis and centrifuge, input was done with the 2.5 % of the crude lysate. Equal amounts of ERRγ or p65 were immunoprecipitated with a preclearing process and incubated overnight at 4 °C with the primary antibody and protein A/G as indicated (SCBT, sc-2003). As control, immunoprecipitation with rabbit IgG (SCBT, sc-11390) was also conducted. After 4 washes with lysis buffer and once with PBS plus inhibitors, pellets were resuspended in 6 x loading buffer, boiled and loaded onto 8 % polyacrylamide gels and transferred to a PVDF membrane (Immobilon-P, Millipore). The expression of interacted proteins was measured by Western blot analysis.

9. Luciferase reporter assay
The promoter activity of ABCB1 or CPT1B was measured according to our previously described protocol [9]. Briefly, the wild type or mutant promoter of ABCB1 or CPT1B were cloned into the pGL3-Basic plasmid and co-transfected with pRL-TK. Transcriptional activity was determined by a luminometer, using a dual luciferase assay kit. Results were displayed as the ratios between the activity of reporter plasmid and pRL-TK.

10. ChIP
The ChIP assay was performed according to our previous study [10]. Briefly, cross-linked and isolated nuclei were sonicated using a Diagenode Bioruptor to an average size of 500 bp in length of treated cells were incubated with 5 μg of anti-ERRγ antibody, rabbit anti-IgG antibody, or no antibody for 16 h at 4°C, followed by incubation with 80 μg of salmon sperm DNA/protein A-agarose for 2 h at 4°C. After washed three times, samples were then treated with RNase A (Roche Diagnostics) for 30 minutes at 37°C and with proteinase K (Roche Diagnostics) for 2 h at 42°C. Isolated DNA fragments were purified with QIAquick spin kit (Qiagen), and quantitative PCRs were performed using 2 μl of DNA in triplicate. The primers were as follow: ABCB1 ERRE1, forward 5’TCA TTT GAA GGT CTT CCC AGT3’, reverse 5’TGG CTT AGG GAT TGG GGT AT3’; ABCB1 ERRE2, forward 5’CCC AAT CCC TAA GCC ATG TA3’, reverse 5’GGA GGA AGG GTG GGA GTA GA3’; CPT1B, forward 5’ GGA GGA ACA ACG AGC AGA AG3’, reverse 5’ CCC AGA GCA CTG AAG AGT CC3’.

11. Metabolic assay
The glucose and lactate concentration in cultured media were measured using commercial kits (BioVision) following the manufacturer’s instructions and previous study [11]. ATP was quantified using CellTiter-Glo® luminescence assay (Promega) according to the manufacturer’s instructions and previous study [12]. All samples were tested in triplicate. PDH activity was measured using the MitoProfile Dipstick Assay Kit (MitoSciences) as previously described [13].

12. ECAR and OCR
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR). ECAR and
OCR were analyzed on a XF96 Extracellular Flux Analyzer (Seahorse Bioscience) as previously described [14]. Cells were plated in non-buffered DMEM media with 10mM glucose. Measurements were obtained under basal conditions and after the addition of 2 μM oligomycin and 100mM 2-DG.

13. Mitochondrial DNA assay
Mitochondrial DNA (mtDNA) copy number was determined as previously described [15]. Briefly, cells relative content of mtDNA (mtDNA primer set) was checked by qRT-PCR and normalized to that of nuclear DNA (GAPDH primer set). The primers were as follow: mtDNA, forward 5’ ACGCCATAAAACTCTTCACAAAG’, reverse 5’ GGGTTTCATAGTAGAAGAGCGATGGG3’; GAPDH, forward 5’ ACAACTTTTGTATCGTGGAAGG’, reverse 5’ GCCATCACGACACAGAGTTTC 3’;

14. Fatty acid uptake assay
The fatty acid uptake assay was conducted by use of a QBT™ Fatty acid uptake assay kit (Molecular Devices) according to the previous study [16]. Briefly, after extracellular FAs were washed away, cells were followed by the addition of QBT FA-loading buffer to each well. The fluorescence intensity was measured on the PowerScan HT microplate reader. Instrument settings were bottom read, excitation 488/emission 515, with a filter cutoff at 495 nm.

15. Fatty acid oxidation assay
The mitochondria of cells were isolated by using the Cell Mitochondrial Isolation Kit (Beyontime, Jiangsu, China). Then the fatty acid β-oxidation rate was measured by use of the Fatty Acid β-Oxidation Kit from Genmed Scientifics Int USA according to the previous study [17].

16. LC-MS/MS assay for m6A
LC-MS/MS assay for m6A quantification was conducted according to our recent study [18]. Briefly, mRNA was purified from total RNA using oligo dT magnetic beads and incubated
with nuclease P1 (0.5 U, Sigma) and alkaline phosphatase (1 μL, 1 U/μL; Sigma) to digestion. All samples (10 μl for each injection) were separated by a C18 column (Agilent) using reverse-phase ultra-performance liquid chromatography and analyzed by an Agilent 6410 QQQ triple-quadrupole LC mass spectrometer using positive electrospray ionization mode. All nucleosides were quantified by use of retention time and ion mass transitions of 268.0 to 136.0 (A) and 282.1 to 150.0 (m6A). Quantification was calculated using standard curves from standards running in the same batch. Ratio of m6A to A was calculated based on calibration curves.

17. RNA stability

To measure RNA stability, actinomycin D (Act-D, Catalog #A9415, Sigma, U.S.A) at 5 μg/ml was added to cells. After incubation at the indicated times, cells were collected and RNA was isolated for Real time PCR. Half-life (t1/2) of precursor and mature RNA were calculated using ln2/slope.

18. Protein stability

To measure protein stability, cells were treated with cycloheximide (CHX, final concentration 100 μg/ml) during indicated times. The expression of ERRγ was measured through western blot analysis.

19. Subcellular fraction of RNA

The nucleus and cytoplasm were separated by NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL, USA). The fractions were pooled to isolate total RNA by TRIzol reagent for RT-PCR.

20. Protein stability

To measure protein stability, cells were treated with cycloheximide (CHX, final concentration 100 μg/ml) during indicated times. The expression of ERRγ was measured through western blot analysis.
21. Experimental animals and xenograft models

BALB/c nude mice (four weeks old) were purchased from Sun Yat-sen University (Guangzhou, China) Animal Center and raised under pathogen-free conditions. All animal experiments complied with Zhongshan School of Medicine Policy on Care and Use of Laboratory Animals. Both sh-control and sh-ERRγ HepG2/ADR cells ($5 \times 10^6$ per mouse, n=5 for each group) were diluted in 200μL PBS + 200 μL Matrigel (BD Biosciences) and subcutaneously injected into immunodeficient mice. After one week, mice were injected i.v. (bolus) through a tail vein at a 3-day interval with saline solution or Dox in saline solution. The injection volume (approximately 0.1 ml/10g body weight) of micelle solution was adjusted to give 10 mg Dox/kg body weight. Tumor volume and mice weight were monitored with relapsed time. The tumor volume was calculated using the formula $V=\frac{1}{2} \times$ larger diameter $\times$ (smaller diameter)$^2$.

22. Immunohistochemistry (IHC)

Immunohistochemistry was performed to measure expression of target protein according to our previous study [19]. The protein expression was assessed semi-quantitatively by two of the authors. The intensity was scored on a scale of 0 - 3 as negative (0), weak (1), medium (2) or strong (3). The extent of the staining, defined as the percentage of positive stained areas of tumor cells per the whole tumor area, was scored on a scale of 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%). An overall protein expression score (overall score range, 0 to 12) was calculated by multiplying the intensity and positivity scores.

23. Database (DB) search

Data about the expression of ESRRG/METTL3 in liver cancer and normal tissues were further obtained from the Oncomine database (www.oncomine.org) as follows: Guichard liver, TCGA liver, Roessler liver, and Finak breast. The expression profiles of ESRRG among the T stages of liver cancer in patients and its association with ABCB1 were downloaded from LinkedOmics (http://www.linkedomics.org), which is a publicly available portal that includes multi-omics data from all 32 cancer types from TCGA. The LinkedOmics website allowed a flexible exploration of associations between a molecular or clinical attribute of interest and all
other attributes, providing the opportunity to analyse and visualize associations between billions of attribute pairs for each cancer cohort [20].

24. Statistical analyses

Data was reported as mean ± SD from three independent experiments. Data was analyzed by two-tailed unpaired Student's t-test between two groups and by One-Way ANOVA followed by Bonferroni test for multiple comparison. *\(p<0.05\), **\(p<0.01\); NS, no significant.

References

12. Lucantoni F, Dussmann H, Llorente-Folch I, Prehn JHM. BCL2 and BCL(X)I selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically


